Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Belite Bio, Inc. ADR ( (BLTE) ) has provided an update.
Belite Bio reported preliminary, unaudited fourth-quarter and full-year 2025 results on March 2, 2026, alongside a corporate update highlighting a pivotal year for its lead candidate tinlarebant. The company said positive topline data from the global Phase 3 DRAGON trial in adolescent Stargardt disease patients support plans to file a U.S. new drug application in the second quarter of 2026, while enrollment was completed in the DRAGON II trial and the PHOENIX Phase 3 study in geographic atrophy reached full enrollment.
Management noted that tinlarebant has secured multiple U.S., European, and Japanese regulatory designations, bolstering its first-in-class profile in a field with no approved treatments for Stargardt disease and no oral therapies for geographic atrophy. Belite also strengthened its balance sheet with a $402 million underwritten ADS offering, lifting cash and investments to more than $770 million by year-end 2025, even as higher R&D and selling, general and administrative spending widened the annual net loss to $77.6 million as the company scales for potential commercialization.
The most recent analyst rating on (BLTE) stock is a Buy with a $223.00 price target. To see the full list of analyst forecasts on Belite Bio, Inc. ADR stock, see the BLTE Stock Forecast page.
Spark’s Take on BLTE Stock
According to Spark, TipRanks’ AI Analyst, BLTE is a Neutral.
BLTE’s score is driven by solid balance-sheet strength but weighed down by pre-revenue financials and rising cash burn. Technicals are bullish with strong trend support, while valuation remains challenging due to ongoing losses. The latest earnings call was a net positive on regulatory/clinical progress and improved liquidity, despite higher expenses and losses.
To see Spark’s full report on BLTE stock, click here.
More about Belite Bio, Inc. ADR
Belite Bio, Inc. is a San Diego-based, clinical-stage drug development company focused on novel therapeutics for degenerative retinal diseases with significant unmet medical need. Its lead oral candidate, tinlarebant, targets retinol binding protein 4 to reduce toxic vitamin A byproducts, and is being developed for Stargardt disease type 1 and geographic atrophy in dry age-related macular degeneration.
Average Trading Volume: 226,289
Technical Sentiment Signal: Buy
Current Market Cap: $6.64B
See more insights into BLTE stock on TipRanks’ Stock Analysis page.